The Pre-Decisional IDE: FDA’s New Proposal To Help Studies Get Started Right
Executive Summary
FDA detailed its proposal for a new “pre-decisional IDE review process” in a revised draft guidance issued June 14. The voluntary process would occur prior to IDE submission and would offer companies comprehensive feedback on where their study plans fall short in gaining IDE approval and in ultimately gaining marketing approval.
You may also be interested in...
FDA To Re-Issue Draft Guidance On Investigational Device Exemption Standards
The device center is responding to a provision in the FDA Safety and Innovation Act, passed last summer, which explicitly prohibits FDA from disapproving an IDE solely because the agency does not believe the study could support approval or clearance.
FDA Addresses Pre-Submission Meetings In Draft Guidance
With the draft guidelines, FDA takes a step toward fulfilling one of its commitments under the reauthorized device user fee program to establish a more structured process for pre-submission meetings with industry.
Jumpstarting U.S. Device Trials? FDA Makes Effort In New Draft Guidelines
New FDA guidances aim to strike a balance by allowing firms to begin trials earlier through adaptive study designs, while ensuring that patients are adequately protected.